Related Experiment Video
Updated: Aug 9, 2026
09:52
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
[Primary biliary cirrhosis: therapy and prognosis]
Nihon Rinsho. Japanese Journal of Clinical Medicine
|January 1, 1994
Summary
Primary biliary cirrhosis (PBC) is an autoimmune liver disease. Combination therapy with ursodeoxycholic acid and colchicine shows promise for improving symptoms and survival in PBC patients.
Area of Science:
- Hepatology
- Immunology
- Gastroenterology
Context:
- Primary biliary cirrhosis (PBC) is an autoimmune liver disease.
- Liver injury in PBC involves cholestasis and toxic bile acid accumulation.
- Current treatments include ursodeoxycholic acid, colchicine, corticosteroids, penicillamine, azathioprine, and cyclosporine A.
Purpose:
- To evaluate the efficacy and safety of combination therapy for PBC.
- To assess the impact of combination therapy on symptoms and biochemical markers.
- To explore the long-term survival outcomes for PBC patients.
Summary:
- Combination therapy with ursodeoxycholic acid and colchicine is effective and safe for PBC.
- Clinical trials demonstrate significant improvements in symptoms and biochemical parameters.
- This combination therapy may prolong survival, especially in asymptomatic patients.
Impact:
- Combination therapy offers a promising treatment approach for Primary Biliary Cirrhosis.
- Improved patient outcomes and prolonged survival are potential benefits.
- Liver transplantation remains the only option for end-stage PBC.
More Related Videos
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
05:22Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
Published on: February 13, 2026
Related Concept Videos
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:30Acute Pancreatitis II: Clinical Manifestations and Management
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:21Chronic Pancreatitis II: Pathophysiology
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...